Century deal hands BMS another chance to be an early mover, with iPS immune cells, γδ T cells

BMS is teaming up with Philadelphia-based Century in a deal that brings the pioneering immuno-oncology pharma into a new technology space — iPS-derived immune cell therapies — and sets it up to be among the  first movers in γδ T cell therapies. 

On Monday, the companies announced a partnership to develop and commercialize up to four induced pluripotent stem (iPS) cell-derived engineered NK and T cell therapies based on Century’s platform. ...